Tuesday, June 7, 2016

UPDATE 1-Biogen's MS drug misses main goal in mid-stage study

June 7 (Reuters) - Biogen Inc's keenly watched

experimental drug for treating multiple sclerosis, a nervous

system disease affecting the brain and the spinal cord, did not

meet the main goal of...

Read more
Posted by at

No comments:

Post a Comment

Subscribe to: Post Comments (Atom)